⚠️ Research Use Only. This post is educational and does not constitute medical advice. All peptides discussed are sold for research purposes only. See our full disclaimer.
Overview
DSIP is a nonapeptide studied for sleep modulation, stress response, and chronic pain research.
What is DSIP?
DSIP, or Delta Sleep-Inducing Peptide, is a small nonapeptide first isolated from the cerebral venous blood of rabbits in 1977. Despite its name suggesting a clear sleep mechanism, the actual pharmacology is poorly understood — researchers have looked for a specific DSIP receptor for decades without finding one.
What the research does show is a complex set of effects. DSIP modulates delta-wave sleep architecture in some studies, reduces stress-induced cortisol elevations, and has been studied in opioid and alcohol withdrawal contexts. A small body of research has examined DSIP in chronic pain conditions, particularly chronic primary insomnia and fibromyalgia.
The peptide's extremely short plasma half-life (around 7 minutes) creates an obvious puzzle — clinical effects appear to outlast circulating peptide levels, suggesting either rapid CNS uptake, downstream signaling, or as-yet-undiscovered active metabolites.
Research dosing typically uses 100-500 mcg subcutaneous, often timed pre-sleep. Some protocols use intranasal administration. The peptide is one of the more affordable research compounds, partly because of how little clinical interest there has been over the last few decades. Most modern interest comes from the biohacking community rather than pharmaceutical research.
Top Research Uses
- Sleep architecture research
- Stress modulation
- Chronic pain research
- Withdrawal symptom research
- Circadian regulation
Mechanism of Action
Modulates limbic system activity, influences delta wave sleep, and interacts with opioid and corticosteroid systems
Research Parameters
| Half-Life | ~7 minutes in plasma |
| Typical Research Dose | Research literature cites 100-500 mcg subq, often pre-sleep |
| Administration Route | Subcutaneous, intranasal |
| Reported Side Effects | Generally minimal; occasional vivid dreams or headache reported anecdotally |
Dosing ranges cited from published research literature. These are not recommendations for human use. DSIP is a research compound — not for human consumption.
Research Strength: Low-Moderate
DSIP has a small but growing body of research. Most evidence is preclinical with limited human data.
Vendor & Sourcing Notes
Available from most research peptide suppliers; relatively inexpensive
Always request third-party HPLC purity reports and mass spectrometry verification when sourcing research peptides. Quality varies significantly between suppliers.
Research Use Only — Compliance Notice
The information on this page is intended for educational and informational purposes only. DSIP (Delta Sleep-Inducing Peptide) is a research compound sold for laboratory research purposes only. It has not been approved by the FDA for human use. Nothing on this page constitutes medical advice or is intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA. Consult a qualified healthcare professional before considering any peptide-related protocols.
